The Binopharm Group holding, combining the Sistema AFC pharmaceutical assets, and the Indian pharmaceutical manufacturer Glenmark Pharmaceuticals agreed to localize the producing of favipiravir used in Russia for COVID-19. The group’s companies will be engaged in both the supply of the drug produced in India and its production at two Russian plants.
Documents for obtaining a registration certificate were submitted to the Ministry of Health of the Russian Federation in November 2020.
“After completing the necessary procedures, we will promptly begin the supply of this drug produced for us under contract at the Glenmark plant in India, which is certified according to Russian GMP standards, and also localize the production of favipavir at our sites,” said Rustem Muratov, CEO of Binnofarm Group.
The production of favipiravir based on the Glenmark substance is planned to develop at the Alium plants in the Moscow Region in Obolensky and Biocom in Stavropol.
At the moment, favipiravir is registered with four Russian manufacturers – Promomed, R-Farm, JV HimRar with RDIF (Kromis) and Pharmasintez. The substance of all manufacturers is Russian, excepting Kromis, which can use the substance produced in China.
